Tapinarof

Generic Name
Tapinarof
Brand Names
Vtama
Drug Type
Small Molecule
Chemical Formula
C17H18O2
CAS Number
79338-84-4
Unique Ingredient Identifier
84HW7D0V04
Background

Tapinarof is a novel, first-in-class, small-molecule AhR agonist that is indicated for the treatment of adult psoriasis. It is available as a topical cream to be applied to the affected area once daily. Tapiranof was first discovered as a metabolite (3,5-dihydroxy-4-isopropylstilbene) produced in Photorhabdus luminescens, a gram-negative bacillus that lives ...

Indication

Tapinarof is indicated for the topical treatment of plaque psoriasis in adults.

Associated Conditions
Psoriasis Vulgaris (Plaque Psoriasis)
Associated Therapies
-
Clinical Trials
Related News

Tapinarof for Cutaneous Lupus Erythematosus

Early Phase 1
Not yet recruiting
Conditions
Cutaneous Lupus Erythematosus
Interventions
Drug: Tapinarof
First Posted Date
2024-10-28
Last Posted Date
2024-10-28
Lead Sponsor
Northwestern University
Target Recruit Count
10
Registration Number
NCT06661213
Locations
🇺🇸

Northwestern University Department of Dermatology, Chicago, Illinois, United States

Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma

Phase 2
Recruiting
Conditions
Palmoplantar Keratoderma
Interventions
Drug: Tapinarof
First Posted Date
2024-08-20
Last Posted Date
2024-12-20
Lead Sponsor
Indiana University
Target Recruit Count
6
Registration Number
NCT06561321
Locations
🇺🇸

Indiana University Department of Dermatology, Indianapolis, Indiana, United States

Vtama in Psoriasis Patients Being Treated With Biologics.

Phase 4
Completed
Conditions
Psoriasis
Interventions
Drug: Tapinarof
First Posted Date
2023-10-27
Last Posted Date
2023-10-27
Lead Sponsor
Psoriasis Treatment Center of Central New Jersey
Target Recruit Count
30
Registration Number
NCT06103695
Locations
🇺🇸

Schweiger Derm Group, East Windsor, New Jersey, United States

Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)

First Posted Date
2023-08-08
Last Posted Date
2024-08-22
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
40
Registration Number
NCT05981118
Locations
🇺🇸

Wake Forest University Health Sciences Department of Dermatology, Winston-Salem, North Carolina, United States

Phase IV Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Psoriasis in Adults

Phase 4
Recruiting
Conditions
Psoriasis
Interventions
Drug: Benvitimod
First Posted Date
2021-10-01
Last Posted Date
2021-10-01
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
2000
Registration Number
NCT05064748
Locations
🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)

Phase 3
Completed
Conditions
Plaque Psoriasis
Interventions
Drug: Vehicle Cream
Drug: Tapinarof
First Posted Date
2019-06-12
Last Posted Date
2022-10-13
Lead Sponsor
Dermavant Sciences GmbH
Target Recruit Count
515
Registration Number
NCT03983980
Locations
🇨🇦

Dermavant Investigative Site, Ottawa, Ontario, Canada

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)

Phase 3
Completed
Conditions
Plaque Psoriasis
Interventions
Drug: Vehicle Cream
Drug: Tapinarof
First Posted Date
2019-05-20
Last Posted Date
2022-10-13
Lead Sponsor
Dermavant Sciences GmbH
Target Recruit Count
510
Registration Number
NCT03956355
Locations
🇨🇦

Dermavant Investigative Site, Montréal, Quebec, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy